Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community

NARecruitingINTERVENTIONAL
Enrollment

5,600

Participants

Timeline

Start Date

November 21, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Type 2 DiabetesCardiovascular ComplicationDiabetic Kidney Disease
Interventions
OTHER

Intensive guideline algorithm implementation

Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C\<7%, control blood pressure \<130/80mmHg, LDL-c\<1.8mmol/L at very high CV risk patients or \<2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.

OTHER

Conventional guideline algorithm implementation

The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.

Trial Locations (13)

215006

RECRUITING

Caohu Community Healthcare Center, Suzhou

RECRUITING

Huangqiao Community Healthcare Center, Suzhou

215131

RECRUITING

Xiangcheng People's Hospital., Suzhou

RECRUITING

Yuanhe Community Healthcare Center, Suzhou

215134

RECRUITING

Xiangcheng Third People's Hospital, Suzhou

215137

RECRUITING

Taiping Community Healthcare Center, Suzhou

215138

RECRUITING

Yangchenghu People's Hospital, Suzhou

215141

RECRUITING

Health Center of Xiangcheng Tourism Resort, Suzhou

215144

RECRUITING

Caohu People's Hospital, Suzhou

215152

RECRUITING

Dongqiao Community Healthcare Center, Suzhou

215155

RECRUITING

Xiangcheng Traditional Chinese Medicine Hospital, Suzhou

215501

RECRUITING

Xiangcheng Second People's Hospital, Suzhou

Unknown

RECRUITING

Chengyang Community Healthcare Center, Suzhou

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER